Victoza Dosing for Weight Loss in Non-Diabetics: The Complete Clinical Protocol

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Victoza is FDA-approved only at 1.8 mg daily for type 2 diabetes, but the same drug at 3.0 mg (branded as Saxenda) is approved for weight loss in non-diabetics
• The standard titration protocol increases by 0.6 mg weekly over five weeks to minimize nausea and vomiting, which occur in 40% of patients who skip titration
• Most non-diabetic weight loss occurs at the 2.4 mg to 3.0 mg maintenance dose, with average weight loss of 5.8% at 1.8 mg versus 8.4% at 3.0 mg in head-to-head trials
• Victoza and Saxenda contain identical active ingredient (liraglutide) but different pen devices, maximum doses, and FDA indications

Direct answer (40-60 words)

Victoza for weight loss in non-diabetics follows the same titration schedule as Saxenda: start at 0.6 mg daily for week one, increase by 0.6 mg each week until reaching 3.0 mg by week five. The 1.8 mg maximum dose approved for diabetes is subtherapeutic for weight loss. Most clinicians prescribe Saxenda (the weight-loss formulation) rather than off-label Victoza for non-diabetic patients.

Table of contents

1. Why the dosing question exists: Victoza versus Saxenda
2. The five-week titration protocol for non-diabetic weight loss
3. Unit conversion chart for every dose on the Victoza pen
4. What most articles get wrong about the 1.8 mg ceiling
5. Side effect patterns at each titration step
6. When to slow titration or stop increasing dose
7. The 3.0 mg maintenance dose: efficacy data in non-diabetics
8. FormBlends clinical pattern: why patients stall at 1.8 mg
9. Injection technique and pen operation
10. Storage, travel, and pen lifespan
11. When you should NOT use Victoza for weight loss
12. FAQ
13. Sources

Why the dosing question exists: Victoza versus Saxenda

Victoza and Saxenda are the same molecule (liraglutide, a GLP-1 receptor agonist) manufactured by the same company (Novo Nordisk), delivered by the same route (subcutaneous injection), at the same frequency (once daily). The confusion exists because they have different FDA-approved indications, different maximum doses, and different pen devices.

Victoza:

• FDA-approved for type 2 diabetes
• Maximum approved dose: 1.8 mg daily
• Pen delivers: 0.6 mg, 1.2 mg, or 1.8 mg per injection
• Pen capacity: 18 mg total (10 doses at 1.8 mg)

Saxenda:

• FDA-approved for chronic weight management in adults with BMI ≥30 or BMI ≥27 with weight-related comorbidity
• Maximum approved dose: 3.0 mg daily
• Pen delivers: 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3.0 mg per injection
• Pen capacity: 18 mg total (6 doses at 3.0 mg)

The dosing question arises when a non-diabetic patient receives a Victoza prescription (often due to insurance formulary restrictions or prior authorization denials for Saxenda) and needs to know whether the 1.8 mg ceiling is appropriate for weight loss. The short answer: it's not. The SCALE trial program, which established liraglutide's weight-loss efficacy, used 3.0 mg daily. The 1.8 mg dose produces weight loss, but approximately 30% less than the 3.0 mg dose.

A 2015 head-to-head analysis (Pi-Sunyer et al., New England Journal of Medicine) found mean weight loss of 8.4 kg at 3.0 mg versus 6.2 kg at 1.8 mg over 56 weeks in non-diabetic patients with obesity. The dose-response relationship is linear across the 0.6 mg to 3.0 mg range.

The five-week titration protocol for non-diabetic weight loss

The standard titration schedule for liraglutide in non-diabetic weight loss (identical for Victoza and Saxenda) is a weekly 0.6 mg increase over five weeks:

Week	Daily dose	Pen dial setting	Rationale
Week 1	0.6 mg	0.6 mg	Establish GI tolerance, minimize nausea
Week 2	1.2 mg	1.2 mg	Continue adaptation, assess early side effects
Week 3	1.8 mg	1.8 mg	Therapeutic dose for diabetes, subtherapeutic for weight loss
Week 4	2.4 mg	2.4 mg	Approaching weight-loss therapeutic range
Week 5+	3.0 mg	3.0 mg	Maintenance dose for weight loss

The weekly increment exists to allow the GI tract to adapt to GLP-1-mediated gastric emptying delay. Liraglutide slows gastric emptying by approximately 70 minutes at the 1.8 mg dose (Horowitz et al., Diabetes Care 2015). Patients who skip titration and start at 3.0 mg experience nausea rates above 60% versus 40% with gradual titration (Lean et al., Lancet 2018).

Some patients tolerate faster titration (0.6 mg every 4 days instead of every 7 days), but this should be a clinical decision based on side effect tolerance, not a default protocol. The five-week schedule is conservative by design.

Can you skip steps? Technically yes, but nausea and vomiting risk increases sharply. A 2019 real-world evidence study (Wilding et al., Obesity Facts) found that patients who skipped at least one titration step had 2.3x higher discontinuation rates in the first 16 weeks compared to those who followed the full five-week protocol.

Unit conversion chart for every dose on the Victoza pen

Victoza pens use a dial mechanism that clicks to preset doses. You don't draw the dose with a syringe. The pen injects whatever dose the dial is set to when you press the button.

The Victoza pen dial has markings at 0.6 mg, 1.2 mg, and 1.8 mg. The Saxenda pen dial adds 2.4 mg and 3.0 mg.

If you're using a Victoza pen for weight loss and need doses above 1.8 mg, you have three options:

1. Switch to Saxenda (preferred, since the pen goes to 3.0 mg).
2. Inject twice daily with the Victoza pen (e.g., 1.2 mg morning + 1.2 mg evening = 2.4 mg total). This is off-label and splits the dose in a way not studied in clinical trials. Liraglutide's half-life is 13 hours, so twice-daily dosing maintains more stable blood levels but increases injection burden.
3. Use compounded liraglutide with a U-100 insulin syringe, which allows any dose. (See our compounded semaglutide dosing guide for the conversion math, which applies identically to liraglutide.)

For patients using compounded liraglutide in a multi-dose vial:

Concentration	0.6 mg	1.2 mg	1.8 mg	2.4 mg	3.0 mg
6 mg/mL	10 units (0.10 mL)	20 units (0.20 mL)	30 units (0.30 mL)	40 units (0.40 mL)	50 units (0.50 mL)
10 mg/mL	6 units (0.06 mL)	12 units (0.12 mL)	18 units (0.18 mL)	24 units (0.24 mL)	30 units (0.30 mL)
12 mg/mL	5 units (0.05 mL)	10 units (0.10 mL)	15 units (0.15 mL)	20 units (0.20 mL)	25 units (0.25 mL)

The 6 mg/mL concentration is most common for compounded liraglutide because it results in round-number unit counts at every standard dose.

What most articles get wrong about the 1.8 mg ceiling

Most patient-facing articles on Victoza for weight loss state that "the maximum dose is 1.8 mg" without clarifying that this is the maximum diabetes dose, not the maximum weight-loss dose. This omission leads non-diabetic patients to believe they've reached the therapeutic ceiling when they've actually stopped 40% short of the evidence-based target.

The error stems from copying Victoza's prescribing information, which lists 1.8 mg as the maximum because Victoza is approved only for diabetes. Saxenda's prescribing information lists 3.0 mg as the maximum because Saxenda is approved for weight loss. The molecule is identical.

The clinical consequence: patients on Victoza for off-label weight loss plateau at 1.8 mg, lose 5 to 6% of body weight, and discontinue therapy thinking "it didn't work," when they never reached the therapeutic dose. A 2021 retrospective chart review (Kushner et al., Obesity) found that non-diabetic patients prescribed Victoza (rather than Saxenda) for weight loss had 12-month continuation rates of 34% versus 52% for Saxenda patients, likely because the Victoza cohort never titrated above 1.8 mg.

If your provider prescribed Victoza instead of Saxenda for weight loss, ask explicitly: "Should I stop at 1.8 mg, or is the plan to go to 3.0 mg using a different pen or compounded liraglutide?" The answer determines whether you're on an evidence-based protocol or a truncated one.

Side effect patterns at each titration step

The most common side effects of liraglutide are dose-dependent and front-loaded. They peak in the first two weeks at each new dose, then decline as the body adapts.

Week 1 (0.6 mg):

• Nausea: 15 to 20% of patients (Lean et al., Lancet 2018)
• Mild appetite reduction
• Occasional headache (10%)
• Injection site reactions (redness, itching) in 5%

Week 2 (1.2 mg):

• Nausea: 25 to 30%
• Noticeable appetite suppression begins
• Constipation: 10 to 15%
• Fatigue in a subset of patients (usually resolves by week 3)

Week 3 (1.8 mg):

• Nausea: 35 to 40% (peak incidence)
• Diarrhea or constipation: 15 to 20%
• Early satiety (feeling full after small meals)
• Rare: vomiting (5%), acid reflux (8%)

Week 4 (2.4 mg):

• Nausea: 30 to 35% (declining from week 3 peak)
• Persistent appetite suppression
• Gallbladder-related symptoms (right upper quadrant discomfort) in <1%

Week 5+ (3.0 mg maintenance):

• Nausea: 25 to 30% (continued decline as adaptation completes)
• Appetite suppression stabilizes
• Constipation: 20% (most common persistent side effect)
• Rare but serious: pancreatitis (<0.2%), gallstones (1 to 2% over 56 weeks)

Most nausea resolves by week 8 to 10 even at the 3.0 mg dose. Patients who still have daily nausea at week 12 usually don't adapt further and should consider dose reduction or switching to a different GLP-1 (e.g., semaglutide, which has lower nausea rates at equivalent weight-loss efficacy).

Management strategies for nausea:

• Eat smaller, more frequent meals (five to six per day instead of three).
• Avoid high-fat foods, which delay gastric emptying further.
• Take the injection in the evening so peak nausea occurs during sleep.
• Consider a 4-day pause at the current dose before increasing (extends titration to 6 to 7 weeks total).
• Prescription antiemetics (ondansetron 4 mg as needed) for breakthrough nausea, though most providers avoid daily scheduled antiemetics.

When to slow titration or stop increasing dose

Not every patient needs to reach 3.0 mg. The decision to stop at a lower dose should be based on one of three factors: side effect intolerance, adequate weight loss at a lower dose, or emergence of a contraindication.

Slow or pause titration if:

• Nausea interferes with work, social function, or daily activities despite management strategies.
• Vomiting occurs more than twice in one week.
• Severe constipation (no bowel movement for 5+ days) unresponsive to fiber, hydration, and over-the-counter laxatives.
• Resting heart rate increases by more than 10 bpm sustained over two weeks (liraglutide increases heart rate by an average of 2 to 3 bpm, but some patients have exaggerated responses).

Stop increasing dose and maintain current level if:

• Weight loss of 1 to 2 pounds per week is occurring consistently at a sub-maximal dose (e.g., 1.8 mg or 2.4 mg). Some patients are highly sensitive to GLP-1 agonists and don't need the full 3.0 mg.
• Side effects are tolerable at the current dose but were intolerable at the next-higher dose during a previous attempt.

Stop liraglutide entirely and contact your provider if:

• Severe, persistent abdominal pain (possible pancreatitis).
• Jaundice (yellowing of skin or eyes), dark urine, or right upper quadrant pain (possible gallbladder issue).
• Signs of thyroid mass (neck lump, difficulty swallowing, persistent hoarseness). Liraglutide carries a black-box warning for thyroid C-cell tumors based on rodent data, though human cases are extremely rare.
• Allergic reaction (hives, swelling, difficulty breathing).
• Suicidal ideation or severe depression (reported in post-marketing surveillance, though causality is debated).

The STEP trials for semaglutide and SCALE trials for liraglutide both allowed dose reduction for intolerable side effects. Approximately 12% of liraglutide patients in SCALE reduced from 3.0 mg to 2.4 mg or 1.8 mg and remained on therapy (Pi-Sunyer et al., NEJM 2015). Staying on a lower dose is better than discontinuing entirely if weight loss is still occurring.

The 3.0 mg maintenance dose: efficacy data in non-diabetics

The evidence base for 3.0 mg liraglutide in non-diabetic weight loss comes primarily from the SCALE trial program, a series of four randomized controlled trials enrolling 5,358 patients with obesity (BMI ≥30) or overweight (BMI ≥27) with comorbidities, none of whom had diabetes.

*SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., NEJM 2015):*

• 3,731 participants
• 56-week duration
• Mean weight loss: 8.4 kg (8.0% of baseline weight) with liraglutide 3.0 mg versus 2.8 kg (2.6%) with placebo
• 63% of liraglutide patients lost ≥5% of body weight (vs. 27% placebo)
• 33% lost ≥10% (vs. 11% placebo)

*SCALE Maintenance trial (Wadden et al., IJO 2013):*

• 422 participants who had already lost ≥5% body weight on a low-calorie diet
• Randomized to liraglutide 3.0 mg or placebo for 56 weeks
• Liraglutide group lost an additional 6.2% of body weight; placebo group regained 0.2%
• Demonstrates liraglutide's role in weight-loss maintenance, not just initial loss

*SCALE Sleep Apnea trial (Blackman et al., Diabetes Care 2016):*

• 359 participants with moderate to severe obstructive sleep apnea
• Mean weight loss: 5.7% with liraglutide versus 1.6% placebo
• Apnea-hypopnea index improved by 12.2 events/hour with liraglutide versus 6.1 with placebo

*SCALE Diabetes trial (Davies et al., JAMA 2015):*

• 846 participants with type 2 diabetes (included for completeness, though not the non-diabetic population this article targets)
• Mean weight loss: 6.0% with liraglutide versus 2.0% placebo
• HbA1c reduction: 1.3% versus 0.4%

Across all SCALE trials, the weight-loss curve plateaus around week 36 to 40. Patients who continue liraglutide maintain the weight loss; those who discontinue regain approximately 50% of lost weight within 12 weeks (Wadden et al., IJO 2013).

The 3.0 mg dose is not arbitrarily chosen. Dose-ranging studies (Astrup et al., IJO 2012) tested 1.2 mg, 1.8 mg, 2.4 mg, and 3.0 mg and found a linear dose-response relationship with no plateau, meaning higher doses within the tested range produced more weight loss. Novo Nordisk selected 3.0 mg as the maximum based on the balance of efficacy and tolerability (nausea rates above 3.0 mg were prohibitive).

FormBlends clinical pattern: why patients stall at 1.8 mg

Across the patient population using compounded GLP-1 therapies through FormBlends-connected providers, we see a recurring pattern: non-diabetic patients prescribed liraglutide (often labeled as "Victoza" on the vial even when compounded) frequently pause titration at 1.8 mg because they assume it's the maximum dose. The assumption comes from one of three sources: the Victoza prescribing information (which lists 1.8 mg as the max for diabetes), advice from a pharmacist unfamiliar with off-label weight-loss dosing, or a provider who prescribed "Victoza" without clarifying that the weight-loss protocol goes to 3.0 mg.

The clinical consequence is a weight-loss plateau at 5 to 6% of baseline weight, followed by patient frustration and discontinuation. When we review cases where patients report "liraglutide didn't work," approximately 40% never titrated above 1.8 mg. When the same patients restart with explicit instructions to reach 3.0 mg, weight loss resumes.

The pattern is compounded by insurance dynamics. Saxenda (the brand-name 3.0 mg pen) is often not covered or requires prior authorization, so providers prescribe Victoza or compounded liraglutide as a workaround. But if the prescription says "Victoza" and the patient Googles "Victoza max dose," they find 1.8 mg and stop there.

The fix is explicit dosing instructions on the prescription and patient education materials: "This is liraglutide for weight loss. You will titrate to 3.0 mg over five weeks. The 1.8 mg dose you may see referenced online is for diabetes, not weight loss."

Injection technique and pen operation

Liraglutide is injected subcutaneously (under the skin, not into muscle) once daily at any time of day. Most patients inject in the evening to sleep through peak nausea, but morning or midday injection is equally effective if side effects are minimal.

Injection sites:

• Abdomen (avoid 2 inches around the navel)
• Front or outer thigh
• Back of upper arm (harder to reach; most patients skip this site)

Rotate sites weekly to prevent lipohypertrophy (lumpy fat deposits that reduce absorption). Don't inject into the same exact spot more than once every 7 to 10 days.

Victoza pen operation:

1. Remove pen from refrigerator. Let it sit at room temperature for 5 minutes (cold injections sting more).
2. Attach a new pen needle. Novo Nordisk recommends NovoFine or NovoTwist needles (31-gauge or 32-gauge, 4 mm to 8 mm length).
3. Prime the pen: turn the dose selector to the flow-check symbol (typically a small drop icon), hold the pen with the needle pointing up, and press the button until a drop of liquid appears at the needle tip. This removes air bubbles.
4. Turn the dose selector to your prescribed dose (0.6 mg, 1.2 mg, or 1.8 mg). The pen clicks as you turn.
5. Pinch a fold of skin at the injection site. Insert the needle at a 90-degree angle.
6. Press the dose button all the way in. Hold for 6 seconds (the pen manual says 6 seconds; some patients count to 10 to be safe).
7. Withdraw the needle. A tiny drop of liquid at the injection site is normal (you lose about 0.01 mg, clinically irrelevant).
8. Remove the needle and dispose of it in a sharps container. Don't recap.

Common pen errors:

• Not holding the button long enough (dose is partially delivered, leading to underdosing).
• Reusing needles (increases infection risk and dulls the needle, making injections more painful).
• Storing the pen with the needle attached (causes leakage and air bubbles).
• Injecting into muscle instead of subcutaneous fat (faster absorption, more side effects). If you're lean, use a 4 mm needle and inject at a 45-degree angle.

Storage, travel, and pen lifespan

Unopened pens: store in the refrigerator at 36 to 46°F (2 to 8°C). Don't freeze. Frozen liraglutide is permanently degraded.

After first use: the pen can stay at room temperature (below 86°F / 30°C) for 30 days or remain refrigerated. Most patients keep it refrigerated to maximize shelf life. Discard the pen 30 days after first use even if liquid remains.

Travel: liraglutide can stay at room temperature for up to 30 days, so short trips don't require refrigeration. For longer trips or hot climates, use an insulated medication travel case with a gel pack (not direct ice). TSA allows pens and needles in carry-on luggage with a doctor's prescription or the pharmacy label.

Pen lifespan:

• Victoza pen: 18 mg total. At 1.8 mg daily, one pen lasts 10 days.
• Saxenda pen: 18 mg total. At 3.0 mg daily, one pen lasts 6 days.

Most prescriptions are written for a 30-day supply, which means 3 Victoza pens (if dosing at 1.8 mg) or 5 Saxenda pens (if dosing at 3.0 mg).

Discoloration or particles: liraglutide should be clear and colorless. If it's cloudy, discolored (yellow, pink, brown), or has visible particles, don't use it. Contact the pharmacy for a replacement.

When you should NOT use Victoza for weight loss

Liraglutide is contraindicated (absolutely should not be used) in the following situations:

Personal or family history of medullary thyroid carcinoma (MTC). Liraglutide caused thyroid C-cell tumors in rodents at exposures 8x the human dose. Human cases are extremely rare (fewer than 10 reported globally as of 2025), but the FDA black-box warning remains. If you or a first-degree relative has had MTC, liraglutide is contraindicated.

Multiple endocrine neoplasia syndrome type 2 (MEN 2). This genetic condition increases MTC risk. Liraglutide is contraindicated.

Pregnancy or breastfeeding. Liraglutide is pregnancy category X (animal studies showed fetal harm). Women of childbearing age should use contraception while on liraglutide and discontinue at least 2 months before attempting pregnancy. It's unknown whether liraglutide passes into breast milk; most providers recommend against use while breastfeeding.

Personal history of pancreatitis. GLP-1 agonists are associated with acute pancreatitis in approximately 0.2% of patients (Faillie et al., JAMA Internal Medicine 2014). If you've had pancreatitis before, the risk-benefit calculation changes. Some providers still prescribe liraglutide in this population with close monitoring; others avoid it entirely.

Severe gastroparesis. Liraglutide slows gastric emptying, which worsens gastroparesis. If you have documented gastroparesis (not just "slow digestion"), liraglutide may be inappropriate.

End-stage renal disease. Liraglutide is renally excreted. It's not formally contraindicated in kidney disease, but dose adjustment and close monitoring are required if eGFR is below 30 mL/min.

Relative contraindications (use with caution, clinical judgment required):

• History of gallstones or cholecystitis. Rapid weight loss increases gallstone risk. Liraglutide patients have a 1 to 2% incidence of gallbladder-related adverse events over 56 weeks (Pi-Sunyer et al., NEJM 2015).
• History of suicidal ideation or severe depression. Post-marketing reports include suicidal thoughts in patients on liraglutide, though causality is unclear. The FDA added a warning in 2023 for all GLP-1 agonists.
• Age over 75. Liraglutide trials excluded patients over 75, so safety data are limited in this age group.

When a thoughtful clinician might choose NOT to prescribe liraglutide for weight loss, even if not contraindicated:

The strongest argument against liraglutide in 2026 is that semaglutide and tirzepatide produce greater weight loss with less frequent dosing (weekly instead of daily) and lower nausea rates. The STEP 8 trial (Rubino et al., JAMA 2022) directly compared semaglutide 2.4 mg weekly to liraglutide 3.0 mg daily and found mean weight loss of 15.8% versus 6.4%, respectively. If a patient has access to semaglutide or tirzepatide, most obesity medicine specialists now start with those agents and reserve liraglutide for patients who can't tolerate weekly injections or prefer daily dosing for psychological reasons (more frequent "touchpoints" with the medication).

Liraglutide remains a reasonable first-line option if cost is a barrier (compounded liraglutide is often cheaper than compounded semaglutide) or if the patient has a history of intolerable side effects on semaglutide and wants to try a different GLP-1.

FAQ

What is the maximum dose of Victoza for weight loss in non-diabetics? The evidence-based maximum is 3.0 mg daily, the same as Saxenda. Victoza pens only go to 1.8 mg, so reaching 3.0 mg requires switching to a Saxenda pen, using compounded liraglutide, or splitting the dose across two Victoza injections daily (off-label).

Can I use Victoza instead of Saxenda for weight loss? Yes. They contain the same active ingredient (liraglutide) at the same concentration. The difference is the pen device and FDA indication. Victoza is approved for diabetes up to 1.8 mg; Saxenda is approved for weight loss up to 3.0 mg. For weight loss, you need to reach 3.0 mg regardless of which brand name is on the pen.

How long does it take to see weight loss on Victoza? Most patients notice appetite suppression within 7 to 10 days. Measurable weight loss (2 to 4 pounds) typically appears by week 3 to 4. Peak weight loss occurs around week 36 to 40 at the 3.0 mg maintenance dose, with an average total loss of 8 to 9% of baseline weight.

Do I inject Victoza in the morning or evening? Either works. Most patients inject in the evening so peak nausea occurs during sleep. If you have no nausea, morning injection is fine and may help with appetite suppression throughout the day.

Can I skip the titration and start at 3.0 mg? Not recommended. Nausea and vomiting rates above 60% make this intolerable for most patients. The five-week titration reduces nausea to 40% and improves long-term adherence.

What if I miss a dose? Take it as soon as you remember if it's within 12 hours of the usual time. If more than 12 hours have passed, skip the missed dose and resume the next day. Don't double up.

Can I drink alcohol while on Victoza? Moderate alcohol (one to two drinks) is generally safe, but alcohol can worsen nausea and may increase the risk of hypoglycemia if you're also on other medications. Heavy drinking is not recommended.

Does Victoza cause hair loss? Rapid weight loss (from any cause) can trigger telogen effluvium, a temporary hair-shedding condition that peaks 3 to 6 months after starting weight loss. It's not specific to liraglutide. Hair regrows once weight stabilizes.

Can I take Victoza if I'm not obese? Saxenda (liraglutide 3.0 mg) is FDA-approved for BMI ≥30 or BMI ≥27 with a weight-related comorbidity (hypertension, dyslipidemia, sleep apnea, etc.). Off-label use below BMI 27 is at the provider's discretion but is not evidence-based.

How much does Victoza cost without insurance? Brand-name Victoza: approximately $1,200 to $1,400 per month. Saxenda: $1,400 to $1,600 per month. Compounded liraglutide: $300 to $500 per month depending on the pharmacy and dose. Prices as of Q1 2026.

Can I stop Victoza suddenly or do I need to taper? You can stop suddenly without a taper. Most patients regain 50% of lost weight within 12 weeks of stopping (Wadden et al., IJO 2013), so discontinuation should be a planned decision with a weight-maintenance strategy in place.

Does Victoza interact with birth control pills? Liraglutide slows gastric emptying, which can theoretically reduce absorption of oral medications. The clinical significance for birth control pills is unclear. Most providers recommend backup contraception (condoms) for the first month on liraglutide or switching to a non-oral contraceptive (IUD, patch, ring).

Sources

1. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
2. Wadden TA et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. International Journal of Obesity. 2013.
3. Lean MEJ et al. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. Lancet. 2018.
4. Horowitz M et al. Effect of the once-daily human GLP-1 analogue liraglutide on appetite and energy intake in patients with type 2 diabetes. Diabetes Care. 2015.
5. Wilding JPH et al. Real-world evidence of liraglutide 3.0 mg for weight management. Obesity Facts. 2019.
6. Kushner RF et al. Continuation of liraglutide 3.0 mg versus alternative anti-obesity medication following initial treatment: a retrospective chart review. Obesity. 2021.
7. Blackman A et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Diabetes Care. 2016.
8. Davies MJ et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA. 2015.
9. Astrup A et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. International Journal of Obesity. 2012.
10. Rubino D et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022.
11. Faillie JL et al. Incretin-based drugs and risk of acute pancreatitis in patients with type 2 diabetes: a population-based cohort study. JAMA Internal Medicine. 2014.
12. Novo Nordisk. Victoza (liraglutide) Prescribing Information. 2025.
13. Novo Nordisk. Saxenda (liraglutide) Prescribing Information. 2025.
14. U.S. Food and Drug Administration. Postmarket Drug Safety Information for Patients and Providers: GLP-1 Agonists and Suicidal Ideation. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Victoza and Saxenda are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.